Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

April 12, 2017

Examining the Link Between Prostate Cancer Treatment and Dementia

Author(s):

Allie Casey

Androgen deprivation therapy, a popular treatment for prostate cancer, may have a link to dementia, according to a recent analysis.

A recent analysis discovered a possible line between androgen deprivation therapy (ADT) — a common treatment for prostate cancer – and dementia.

A previous study done by researchers at the Perelman School of Medicine at the University of Pennsylvania found that men who received ADT may be at an increased risk for dementia, including Alzheimer’s disease, compared with men who were not treated with the therapy. The absolute increased risk of developing dementia, they determined, was 4.4 percent at five years.

Since that study was published in October 2016, researchers have looked into it further. This analysis, published in Prostate Cancer and Prostatic Diseases, looked at data from four different, global databases (PubMed, Web of Science, Embase, PsycINFO), comparing studies on ADT patients and dementia and Alzheimer’s. All the existing studies together, researchers said, support the link to dementia, and show a possible link to Alzheimer’s.

“This analysis tells us that the composite message of existing studies is that androgen deprivation therapy is associated with dementia,” according to Kevin Nead, M.D., MPhil, a radiation oncology resident with the Perelman School of Medicine at the University of Pennsylvania and an author on both studies.

From the four databases, there were nine studies on the outcome of dementia among patients exposed to ADT versus a lesser-exposed comparison group (eg, ADT vs no ADT or continuous ADT vs intermittent). An analysis of 50,541 patients showed an increased risk of dementia among those who had undergone ADT. Nead clarified that this analysis shows correlation, although not causation at this point.

“Research shows androgens play a key role in neuron maintenance and growth, so the longer you undergo this therapy to decrease androgens, the more it may impact the brain’s normal functions,” Nead said.

A link between ADT and Alzheimer’s was found as well, but it was not as clearly defined as the link to dementia.

When the earlier study was published, Nead stated, “It would be really hard to justify not using a medication that we know extends life for a possible negative consequence that at this point is potential, probably at best, but nor proven.”

The more recent analysis suggests that the evidence between ADT and neurocognitive dysfunction continues to grow, said Nead, and should be a part of the conversations between doctors and patients: “There’s enough evidence of these links that patients should know about them when considering their options.”

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Tagawa.
Breaking Down the Benefits of Clinical Trial Participation in Cancer Care
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Crafting an Individual Treatment Plan for Patients With Prostate Cancer
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
NeuroSAFE Increases Erectile Function After Prostate Cancer Surgery
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Xtandi and Talzenna Therapy Shows Responses in Advanced Prostate Cancer
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Better Understanding Genetic Mutations Influence in Cancer Care
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
An Expert Highlights His Key Takeaways From The 2025 ASCO GU Symposium
Image of man with black hair.
Personalized Medicine Makes Strides Across the GU Oncology Treatment Space
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Treatment Intensification Adoption Differences Across Prostate Cancer
Image of Dr. Goy.
Understanding How One Must Interpret PSA Levels in Prostate Cancer
Image of man with brown and grey hair.
How Five-Fraction SBRT Compares With Traditional Radiation in Prostate Cancer
Related Content
Advertisement
Photo of a patient in consultation with a doctor.
April 25th 2025

Decipher Prostate Test Now Available for Metastatic Prostate Cancer

Spencer Feldman
Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
April 15th 2025

Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset

Ashley Chan
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of man and doctor.
April 12th 2025

NeuroSAFE May Increase Erectile Function After Prostate Cancer Surgery

Alex Biese
Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.
Photo of a doctor and patient speaking over a desk
April 9th 2025

PROSTOX May Predict Urinary Side Effects Post Prostate Cancer Radiation

Alex Biese
A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study.
Related Content
Prostate Cancer
Prostate Cancer
Advertisement
Photo of a patient in consultation with a doctor.
April 25th 2025

Decipher Prostate Test Now Available for Metastatic Prostate Cancer

Spencer Feldman
Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
April 15th 2025

Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset

Ashley Chan
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of man and doctor.
April 12th 2025

NeuroSAFE May Increase Erectile Function After Prostate Cancer Surgery

Alex Biese
Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.
Photo of a doctor and patient speaking over a desk
April 9th 2025

PROSTOX May Predict Urinary Side Effects Post Prostate Cancer Radiation

Alex Biese
A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study.
Advertisement
Advertisement
Advertisement
x
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.